Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Nefiracetam and Piracetam — mechanism, side effects, legal status, and pricing.
Nefiracetam is a non-peptide small molecule in the racetam (pyrrolidinone/2-oxopyrrolidine acetamide) class, investigated as a cognitive enhancer. It was never approved by the FDA, EMA, or Japan's PMDA; Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002 after a repeat Phase III trial in dementia failed to demonstrate efficacy. A US/Canada Phase II trial in poststroke depression (600 mg and 900 mg/day) showed no overall separation from placebo, though a subgroup analysis suggested benefit in the most severely depressed patients at 900 mg. No validated therapeutic dose or approved indication exists; it is sold by research-chemical and laboratory-reagent suppliers for research use only.
Piracetam is a non-peptide pyrrolidinone-derivative racetam, the prototypical member of the nootropic racetam class. It is approved in the EU/UK exclusively for adult cortical myoclonus as adjunctive therapy (marketed as Nootropil), but has NO FDA approval in any form in the United States. The FDA has rejected its New Dietary Ingredient notification and issued warning letters to US vendors marketing it as a supplement. Piracetam itself is not WADA-prohibited, though its derivative phenylpiracetam is a banned stimulant.
Nefiracetam
Piracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Nefiracetam
No pricing data yet.
Check Nefiracetam prices →Piracetam
No pricing data yet.
Check Piracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Nefiracetam
2
COAs
99.6%
Avg purity
2
Labs
Piracetam
1
COAs
99.8%
Avg purity
1
Labs
Human clinical data are limited and largely negative or mixed. Japanese Phase II/III trials in dementia/cognitive sequelae after cerebrovascular disorders showed improvement over placebo in some early trials, but a Ministry of Health-mandated repeat Phase III trial under revised guidelines failed to demonstrate efficacy, and Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002. A US/Canada multicenter randomized double-blind Phase II trial (28 sites, 1999–2001, n=159) tested nefiracetam 600 mg and 900 mg/day vs. placebo for poststroke depression; the drug did not separate from placebo overall (response >70%, remission >40% in both arms) but showed significant benefit in the most-severely-depressed subgroup at 900 mg (Robinson et al., J Neuropsychiatry Clin Neurosci 2008). A related post hoc analysis examined apathy outcomes in the same cohort. Preclinical findings include: rat cortical neurons showed potentiation of native α4β2-type nicotinic acetylcholine receptor currents via a G(s)-protein-dependent pathway; rat dorsal root ganglion neurons showed dual concentration-dependent effects on GABA_A receptor-channel currents mediated via cAMP-dependent protein kinase and Gi/Go proteins; rat neuronal preparations showed enhancement of high-voltage-activated N/L-type Ca²⁺ channel currents and modulation of NMDA receptor function via PKC-dependent phosphorylation; rat passive avoidance models showed reversal of apomorphine-induced amnesia and preservation of hippocampal NCAM-mediated memory consolidation during scopolamine disruption.
Piracetam is an approved prescription drug in the EU/UK for adult cortical myoclonus (adjunctive therapy) and has been studied off-label in multiple placebo-controlled human trials for age-related cognitive decline, post-stroke aphasia, post-ECT cognitive deficit, and post-CABG cognitive decline, with mixed results. A Cochrane systematic review (2001) concluded that available evidence does not support piracetam's use for dementia or cognitive impairment beyond a global-impression measure. In rodent models, piracetam reduced focal ischemia infarct volume by ~35.8%, improved neurological/locomotor outcomes and survival, attenuated oxidative stress and excitatory amino acid release in oxygen-glucose deprivation, and showed anticonvulsant and neuroprotective effects in PTZ-induced epilepsy.
Nefiracetam and Piracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs